K. Michael Forrest
Vorstandsvorsitzender bei Apex Bioventures LLC
Profil
K.
Michael Forrest is currently the Chairman & Chief Executive Officer at Apex Bioventures LLC.
Previously, he held positions such as President & Chief Executive Officer at Cellegy Pharmaceuticals, Inc. from 1996 to 2005, President & Chief Executive Officer at Transkaryotic Therapies, Inc. from 1991 to 1994, Co-Chief Executive Officer & Director at Sarepta Therapeutics, Inc. from 2005 to 2010, President & Chief Executive Officer at Mercator Genetics, Inc. from 1994 to 1995, and Chairman at Arbutus Biopharma Corp.
from 2007 to 2010.
He also served as Vice President-Planning & Commercial Development at Wyeth Holdings LLC in 1991 and as Vice President at Lederle Laboratories and Lederle International.
Mr. Forrest received his undergraduate degree from Georgetown University in 1972.
Aktive Positionen von K. Michael Forrest
| Unternehmen | Position | Beginn |
|---|---|---|
| Apex Bioventures LLC | Vorstandsvorsitzender | 01.01.2005 |
Ehemalige bekannte Positionen von K. Michael Forrest
| Unternehmen | Position | Ende |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Vorstandsvorsitzender | 21.04.2010 |
| ARBUTUS BIOPHARMA CORPORATION | Vorsitzender | 28.01.2010 |
Apex Bioventures Acquisition Corp.
 Apex Bioventures Acquisition Corp. Financial ConglomeratesFinance The Company is a blank check company. It is formed to acquire one or more domestic or foreign operating business in the healthcare industry through merger, capital stock exchange, asset acquisition or other similar business combination. The Company is in the development stage. On February 5, 2008, the Company entered into an Agreement and Plan of Merger with Dynogen Pharmaceuticals, Inc and its acting representatives. | Präsident | 04.06.2009 |
Cellegy Pharmaceuticals, Inc.
 Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Präsident | 01.01.2005 |
Mercator Genetics, Inc.
 Mercator Genetics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Progenitor, Inc., Mercator Genetics, Inc. develops gene therapy programs for asthma, schizophrenia, and cancer. The company is based in Menlo Park, CA. Mercator Genetics was acquired by Progenitor, Inc. on February 18, 1997 for $22 million. | Präsident | 01.12.1995 |
Ausbildung von K. Michael Forrest
| Georgetown University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Cellegy Pharmaceuticals, Inc.
Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Health Technology |
Apex Bioventures Acquisition Corp.
Apex Bioventures Acquisition Corp. Financial ConglomeratesFinance The Company is a blank check company. It is formed to acquire one or more domestic or foreign operating business in the healthcare industry through merger, capital stock exchange, asset acquisition or other similar business combination. The Company is in the development stage. On February 5, 2008, the Company entered into an Agreement and Plan of Merger with Dynogen Pharmaceuticals, Inc and its acting representatives. | Finance |
| Apex Bioventures LLC | |
Mercator Genetics, Inc.
Mercator Genetics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Progenitor, Inc., Mercator Genetics, Inc. develops gene therapy programs for asthma, schizophrenia, and cancer. The company is based in Menlo Park, CA. Mercator Genetics was acquired by Progenitor, Inc. on February 18, 1997 for $22 million. | Commercial Services |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Lederle Laboratories
 Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Commercial Services |
| Lederle International | |
1322256 Alberta Ltd.
 1322256 Alberta Ltd. Pharmaceuticals: MajorHealth Technology Inex Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. | Health Technology |
Wyeth Holdings LLC
 Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. | Process Industries |
